However, the analysis of MLH1 promoter methylation coupled with clinical and family information has been shown to represent a rational testing surrogate for Lynch syndrome, both in the clinic and in breast cancer translational research studies (9,11,46). This evidence concerns the gene MLH1 and breast carcinoma.